ReviewJournal of diabetes research2022
Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications.
Review in Journal of diabetes research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07084350 (Efficacy and Safety of Oral Lactulose Combined With Polyethylene Glycol Electrolytes Powder), which is not on this map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Oral Lactulose Combined With Polyethylene Glycol Electrolytes Powder (PEG-ELS) for Bowel Preparation in Type II Diabetes Mellitus Patients: A Randomized Controlled Trial
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Temporal Eating Patterns and Colorectal Cancer: A Systematic Review.Current nutrition reports · 2025Pooled it
- Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence studies.BMC gastroenterology · 2025Pooled it
- Pooled it
- Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis.Diabetes & metabolism journal · 2024Pooled it
- Temporal Trends in Colorectal Cancer Associated With Type 2 Diabetes Mellitus in U.S. Adults, 1999-2023: A CDC Wonder Database Analysis-A Population-Based Cross-Sectional Study.Health science reports · 2026Article
- Article
- Fermented NaDES-Ginger Extract Attenuates Hyperglycemia-Driven Inflammation and Endothelial Adhesion in Colorectal Cancer Through the NF-κB/COX-2 Axis.Life (Basel, Switzerland) · 2026Article
- High glucose enhances NScientific reports · 2026Article
- Metformin in gastrointestinal cancers and inflammatory bowel disease: Unraveling its mechanisms and therapeutic applications.iScience · 2026Review
- Genetic underpinnings of type-2 diabetes (T2D) with colorectal cancer (CRC): In-silico discovery of common molecular signatures, pathogenetic processes and therapeutic candidates.Journal, genetic engineering & biotechnology · 2026Article
- Hyperglycemia drives lmmune evasion in colorectal cancer through VISTA stabilization.Cell communication and signaling : CCS · 2026Article
- The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.International journal of surgery (London, England) · 2026Article
- Long non-coding RNAs in the crosstalk between diabetes and colorectal cancer: molecular mechanisms and endocrine pathways.Frontiers in molecular biosciences · 2026Review
- Long non-coding RNAs as molecular links and circulating biomarkers between type 2 diabetes and colorectal cancer: focus on shared signaling pathways, epigenetic regulation, and ubiquitination mechanisms.Frontiers in molecular biosciences · 2026Review
- Global, regional and national burden of colon and rectum cancer attributable to high fasting plasma glucose: a systematic analysis for the Global Burden of Disease Study 2021.Frontiers in oncology · 2026Article
- Overexpression of lncRNA ATP11A-AS1 in Colorectal Cancer and Its Association WithInternational journal of genomics · 2026Article
- Curcumin in colorectal cancer: preventive strategies and therapeutic mechanisms.Cancer chemotherapy and pharmacology · 2025Review
- Bridging diabetes and cancer: harnessing biomarkers as dual sentinels for diagnosis, prognosis, and therapeutic advancements.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A Clinical Analysis of the Association Between Nifedipine and Insulin Usage and the Increased Incidence of Colonic Polyps.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- A machine learning tool for identifying metastatic colorectal cancer in primary care.Scandinavian journal of primary health care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several epidemiological studies have identified diabetes as a risk factor for colorectal cancer (CRC). The potential pathophysiological mechanisms of this association include hyperinsulinemia, insulin-like growth factor (IGF) axis, hyperglycemia, inflammation induced by adipose tissue dysfunction, gastrointestinal motility disorder, and impaired immunological surveillance. Several studies have shown that underlying diabetes adversely affects the prognosis of patients with CRC. This review explores the novel anticancer agents targeting IGF-1R and receptor for advanced glycation end products (RAGE), both of which play a vital role in diabetes-induced colorectal tumorigenesis. Inhibitors of IGF-1R and RAGE are expected to become promising therapeutic choices, particularly for CRC patients with diabetes. Furthermore, hypoglycemic therapy is associated with the incidence of CRC. Selection of appropriate hypoglycemic agents, which can reduce the risk of CRC in diabetic patients, is an unmet issue. Therefore, this review mainly summarizes the current studies concerning the connections among diabetes, hypoglycemic therapy, and CRC as well as provides a synthesis of the underlying pathophysiological mechanisms. Our synthesis provides a theoretical basis for rational use of hypoglycemic therapies and early diagnosis and treatment of diabetes-related CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.